104 related articles for article (PubMed ID: 38766697)
1. Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer.
Hashimoto K; Kaira K; Imai H; Shiono A; Kagamu H
J Chemother; 2024 May; ():1-3. PubMed ID: 38766697
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
McCoach CE; Rolfo C; Drilon A; Lacouture M; Besse B; Goto K; Zhu VW; Tan DSW; Farajian S; Potter LA; Kherani JF; Soldatenkova V; Olek EA; Muehlenbein CE; Park K
J Thorac Oncol; 2022 Jun; 17(6):768-778. PubMed ID: 35183775
[TBL] [Abstract][Full Text] [Related]
3. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
4. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
Nie T; Syed YY
Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immune checkpoint inhibitor therapy in patients with
Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
[TBL] [Abstract][Full Text] [Related]
6. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
[TBL] [Abstract][Full Text] [Related]
7. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
[TBL] [Abstract][Full Text] [Related]
8. Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer.
Yokota T
Case Rep Oncol; 2022; 15(3):833-840. PubMed ID: 36825106
[TBL] [Abstract][Full Text] [Related]
9. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
10. An 83-year-old patient with RET fusion-positive non-small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration.
Nakashima K; Mitarai Y; Tanaka S; Nakao M; Okuno T; Okimoto T; Tanabe R; Yanagawa T; Tsubata Y; Isobe T
Respirol Case Rep; 2023 May; 11(5):e01136. PubMed ID: 37051304
[TBL] [Abstract][Full Text] [Related]
11. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
[TBL] [Abstract][Full Text] [Related]
12. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
Nguyen VQ; Geirnaert M
J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
[TBL] [Abstract][Full Text] [Related]
13. Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in
Scattolin D; Scagliori E; Scapinello A; Fantin A; Guarneri V; Pasello G
Front Oncol; 2023; 13():1201599. PubMed ID: 37492479
[TBL] [Abstract][Full Text] [Related]
14. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Le D; Konda B
Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
[TBL] [Abstract][Full Text] [Related]
15. Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.
Meng Z; Zhang C; Zuo R; Zhu F; Wang Y; Mi R; Zhang M; Chen P
Anticancer Drugs; 2022 Aug; 33(7):682-685. PubMed ID: 35324532
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Rotow J; Patel JD; Hanley MP; Yu H; Awad M; Goldman JW; Nechushtan H; Scheffler M; Kuo CS; Rajappa S; Harada G; Clifford S; Santucci A; Silva L; Tupper R; Oxnard GR; Kherani J; Drilon A
Clin Cancer Res; 2023 Aug; 29(16):2979-2987. PubMed ID: 36996322
[TBL] [Abstract][Full Text] [Related]
17. Selpercatinib and capmatinib combination promotes sustained complete response in novel
Leite CA; Carvalho RP; da Costa FM; Medeiros AK; Schutz FA; William WN
Front Oncol; 2023; 13():1264231. PubMed ID: 37876974
[No Abstract] [Full Text] [Related]
18. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in
Zhou C; Solomon B; Loong HH; Park K; Pérol M; Arriola E; Novello S; Han B; Zhou J; Ardizzoni A; Mak MP; Santini FC; Elamin YY; Drilon A; Wolf J; Payakachat N; Uh MK; Rajakumar D; Han H; Puri T; Soldatenkova V; Lin AB; Lin BK; Goto K;
N Engl J Med; 2023 Nov; 389(20):1839-1850. PubMed ID: 37870973
[TBL] [Abstract][Full Text] [Related]
19. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
[TBL] [Abstract][Full Text] [Related]
20. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
